On November 28, 2016 Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, reported that the company will present preclinical data highlighting the development of its lead molecule BT1718 (Press release, Bicycle Therapeutics, NOV 28, 2016, View Source [SID1234516821]). This program is the first example of its Bicycle Drug Conjugate technology which allows toxins to be targeted to tumour types of high unmet medical need. These data will be presented at the 28th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) 2016 Symposium on Molecular Targets and Therapeutics to be held in Munich, Germany from November 29th through December 2nd, 2016.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the poster presentations at the 28th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) are as follows:

Title: Development of BT1718, a Bicycle Drug Conjugate (BDC) targeting MT1-MMP for treatment of solid tumours

Session: Molecular target agents 1

Poster #: P013

Date & Time: Nov. 29, 11:45 a.m. – 6:30 p.m. CET

Title: Design and characterization of a high affinity and selective bicyclic peptide binder to MT1-MMP for development of a treatment for solid tumours

Session: Drug Design

Poster #: P024

Date & Time: Nov. 30, 10:15 a.m. – 5:00 p.m. CET